Compare Enveric Biosciences Inc (ENVB) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs H2O America — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while H2O America trades at $58.31 (market cap $2.43B). The key difference: H2O America is far larger — about 363.2× Enveric Biosciences Inc's market cap, and H2O America pays a 3.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and H2O America for 40 Days on average.
| ENVB | HTO | |
|---|---|---|
Market Cap | $6.69M | $2.43B |
Volume | 41,141 | 449,654 |
Sector | Health | Utilities |
52-Week High | $10.80 | $65.43 |
52-Week Low | $1.27 | $44.44 |
Typical Hold Time | 14 Days | 40 Days |
Enterprise Value | -$1.60M | $4.21B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
HTO trades at $57.98, down 0.34% today, with a bearish technical signal despite bullish oscillators. The company maintains strong profitability with 12.91% net margin and recently completed the Quadvest acquisition in Texas. Earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 missing estimates.
Analyst consensus remains bullish with 83% buy ratings and $66.50 price target, representing 15% upside. Key risks include acquisition integration challenges and negative cash flow from investing activities. The stock offers dividend income with recent $0.44 dividend declaration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
